REBIRTH Members

Manns, Michael Peter

Manns, Michael Peter, Prof. Dr. med.

Department of Gastroenterology, Hepatology and Endocrinology

Hannover Medical School
Podbielskistr. 380
30659 Hannover

Manns.Michael(at)mh-hannover.de

Biography / About

Date of Birth:November, 1951
Function:Head of the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School (MHH)

Education:

1970 - 1976Medical School, Vienna, Austria, and Mainz, Germany
1976Doctor of Medicine, MD
1977Licence as MD
1984Licence for Internal Medicine
1985Subspecialist for Gastroenterology and Hepatology
1986Professor of Medicine and Gastroenterology, University of Mainz, Germany

Academic appointments and Research posts:

1977 - 1981Resident, Department of Internal Medicine, Free University of Berlin, Germany
1981 - 1985Resident, Department of Medicine I, University of Mainz, Germany
1985 - 1991Senior Physician (Oberarzt), Deptartment of Medicine I, University of Mainz, Germany
1987 - 1988Research Associate, Scripps Research Foundation, La Jolla, CA, USA
Since 1991Head, Department of Gastroenterology, Hepatology and Endocrinology, MHH
1997 - 1999Medical Director, MHH
1997 - 2003Chairman, DFG CRC ‘SFB 265: Immunreaction and Pathomechanismen by Organtransplantation’
Since 2002Chairman of Hep-Net / National network of excellence on viral hepatitis
Since 2007Spokesperson DFG collaborative research center (CRC) ‘SFB 738: Optimisation of Conventional and Innovative Transplants’
2011 - 2014Co-Founder and Vicechair DFG CRC/Transregio ‘TRR 77: Liver Cancer - From Molecular Pathogenesis to Targeted Therapies’
Since 2015Director, Centre for Individualised Infection Medicine (CIIM), Hannover
Since 2015Clinical Director, Helmholtz Centre for Infection Research (HZI), Braun-schweig, Germany

Other professional activities:

Since 2002Member, Leopoldina, National Academy of Science, Halle, Germany
2006President, German Society of Gastroenterology (DGVS)
2012Corresponding member, Academy of Science, Mainz, Germany
2013President, German Association for the Study of the Liver (GASL)
2013 - 2014President, German Society of Internal Medicine (DGIM)
Since 2013Member of the Senate, MHH
2016 - 2017President, United European Gastroenterology (UEG)
Since 2015Associate Editor ‘Clinical Gastroenterology and Hepatology‘
Since 2015Member, Scientific Panel of Health (SPH), European Commission

Awards and Prizes:

1991Clemens van Pirquet Award, University of California Davis, CA, USA
1995International Hans Popper Award Basel, Switzerland
2006Corriere della Sera, Milano: MHH Department of Gastroenterology, Hepatology and Endocrinology is leading centre for liver research in Europe
2007EASL Recognition Award, Barcelona, Spain
2014, 2015, 2016Thomson Reuters Highly Cited Researcher (top 1 %)

Major research interests:

  • Liver, transplantation
  • Regenerative medicine
  • Gastrointestinal oncology
  • Immunology

Selected Publications:

  1. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MPP, Kowdley KV, Zeuzem S, for the POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New Engl J Med. 2017. (in press)
  2. Manns MPP, Buti M, Gane EJ, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Nature Reviews Disease Primars - Hepatitis C virus infection. Nat Rev Dis Primers. 2017. 3, 17006.
  3. Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, Manns MPP, Ott M, Cantz T, Sharma AD. MicroRNA-125b-5p mimic inhibits acute liver failure. Nat Commun. 2016. 7: 11916.
  4. Manns MP, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterbum S, Pang PS, Brainard D, McHutchison JG, Dufour F, Van Vlierberghe H, van Hoek B, Forns X for the SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients withgenotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet Infect Dis. 2016. 16:685-97.
  5. Manns MP, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team, All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. The Lancet. 2014. 384:1597-605
  6. Manns MP, Marcellin P, Poordad F, Affonso de Araujo S A, Buti M, Horsmans Y, Janczewska W, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, de la Rosa G, Kalmeijer R, Sinha R, Beumont-Maiviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis c virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet. 2014. 384: 414-426.
  7. Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, Manns MPP, Zender L. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell. 2013. 153: 389-401.
  8. Wedemeyer H, Yurdaydin C, Dalekos G, Ehrhardt A, Cakaloglu Y, Degertekin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Bock CT, Dienes H, Manns MPP. Peginterferon plus Adefovir versus either drug alone for hepatitis delta. New Engl J Med. 2011. 364: 322 – 331.
  9. Manns MPP, Woynarkowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Gunther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Farkkila M, Proels M, Strassburg CP. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology. 2010. 139: 1198-1206.
  10. Manns MPP Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. AASLD Practice Guidelines: Diagnosis and Management of Autoimmune Hepatitis. Hepatology. 2010. 51: 2193-2213.


[back to listing]
test
This website uses cookies and the web analytics service Google Analytics. Click here for further information on privacy.
I agree